�

�

�

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

�

Grant of Awards under Long Term Incentive Plan

�

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTIP") t he following conditional awards of shares of 0.1 pence each were made to Executive Directors at a nominal cost of 0.1 pence each on 15 March 2018 (the "Awards").

�

�

Executive Director	Number of Conditional shares awarded	Total conditional shares held under LTIPs
Manuel Llobet	900,000	3,435,000
Nick Wykeman	450,000	872,500

�

�

The Awards have been granted in accordance with the LTIP rules and vesting is conditional on the satisfaction of performance conditions in respect of earnings growth and share price growth. �

�

In addition, Manuel Llobet holds share options in respect of 1,529,024 shares relating to a vested LTIP award.

�

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them �

1 �	Details of the person discharging managerial responsibilities / person closely associated �
a) �	Name � �	Manuel Llobet Nicolas Wykeman �
2 �	Reason for the notification �
a) �	Position/status � �	Manuel Llobet - Chief Executive Office and PDMR Nicolas Wykeman - Finance Director and PDMR
b) �	Initial notification /Amendment � �	Initial notification
3 �	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor �
a) �	Name � �	ALLERGY THERAPEUTICS PLC
b) �	LEI � �	213800PQ7AHK7KGVOE23
4 �	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted � �
a) �	Description of the financial instrument, type of instrument � � � �	Conditional award of shares under the Company's Long Term Incentive Plan � � � � �
b)	Identification code	GB00B02LCQ05
c) �	Nature of the transaction � �	Grant of Conditional Awards
d) �	Price(s) and volume(s) � �	� Price(s)   Volume(s) £0.001 900,000 £0.001 450,000
e)	Aggregated information     - Aggregated volume     - Price	N/A (Single transaction)
f)	Date of the transaction	15 March 2018
g)	Place of the transaction	Outside a trading venue

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Corporate Finance

Tom Salvesen, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Philippa Gardner

[email protected]

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .